VivoSeq
Oncology

Adenocarcinoma

281

Pipeline Programs↗

93

Active Trials↗

90

Companies Involved↗

Adenocarcinoma is a highly competitive landscape with 281 programs across 90 companies. The most active players are Sorrento Therapeutics, Inc., Karyopharm Therapeutics Inc, Merck & Co.. 7 therapies are approved with 62 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

87/100

Pipeline Velocity

55/100

Mech. Concentration

6/100

Completion Rate

66/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sorrento Therapeutics, Inc.

1 program

Phase 1K

Karyopharm Therapeutics Inc

1 program

Phase 1Merck & Co. logo

Merck & Co.

3 programs

Phase 2Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

3 programs

Phase 2Eisai logo

Eisai

2 programs

Phase 2Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical13

Systemic Chemotherapy

Sun Yat-sen University

Gemcitabine Hydrochloride

Gynecologic Oncology Group

Adjuvant Chemotherapy

Nizhny Novgorod Regional Clinical Oncology Center

Anti-Angiogenic Drug

Fudan University

Immune Checkpoint Inhibitor

ImmuneSensor Therapeutics Inc.

Phase 126

Tremelimumab

AstraZeneca

Losartan

Organon and Co

IM96 CAR-T Cells

Beijing Immunochina Medical Science & Technology Co., Ltd.

Hydroxychloroquine

Alnylam Pharmaceuticals

Selinexor

Karyopharm Therapeutics Inc

Phase 2173

Olaparib

AstraZeneca

Atezolizumab

Roche

Trastuzumab

Organon and Co

Enzalutamide

Astellas

Enfortumab Vedotin

Pfizer

Phase 362

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Zimberelimab

Arcus Biosciences

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Datopotamab Deruxtecan

Daiichi Sankyo

Zolbetuximab

Astellas

Approved7

Thiotepa

Alnylam Pharmaceuticals

Degarelix

Ferring

Mitomycin

UroGen Pharma Ltd.

Temsirolimus

Prism Pharmaceuticals

Everolimus

Novartis

Analysis

Modality Breakdown

83%

Small molecule

264 of 318 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody3812%Vaccine62%Antibody–drug conjugate3<1%Cell therapy3<1%Protein / enzyme2<1%Peptide1<1%Other1<1%

Small molecule leads; the ring shows all 318 classified programs, each share of the total. Modality classified for 99% of 338 pipeline programs.

Analysis

Trial Status

299

clinical trials

Completed107 · 36%
Unknown status44 · 15%
Recruiting44 · 15%
Terminated36 · 12%
Not yet recruiting25 · 8%
Active, not recruiting22 · 7%
Other21 · 7%

Clinical Trials

Trial Activity

299 trials

Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma
Recruiting·FFudan University·N/A·NCT07389876·250 enrolled
Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach
Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06992362·30 enrolled
The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic Adenocarcinoma
Recruiting·GGuangdong Provincial People's Hospital·Phase 1·NCT06743867·30 enrolled
PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma
Recruiting·—·Phase 3·NCT06813976·294 enrolled
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT04105270·82 enrolled
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT07102901·351 enrolled
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
Recruiting·FFudan University·Phase 3·NCT04997837·433 enrolled
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Recruiting·AAkeso·Phase 3·NCT07023315·760 enrolled
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Recruiting·BBioAtla, Inc.·Phase 1·NCT05808634·168 enrolled
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Recruiting·—·N/A·NCT06417892·60 enrolled
Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction
Recruiting·EErasmus Medical Center·Phase 2·NCT06161818·216 enrolled
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
Recruiting·QQilu Hospital of Shandong University·Phase 2·NCT06932068·77 enrolled
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Recruiting·—·Phase 2·NCT05729646·90 enrolled
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Recruiting·AAcrivon Therapeutics·Phase 2·NCT05548296·353 enrolled
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Recruiting·XXijing Hospital·Phase 2·NCT06576921·116 enrolled
Page 1 of 20

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)